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Antenatal corticosteroid (ACS) therapy for women with anticipated 
preterm delivery stands as one of the major advances in caring for preterm 
infants, together with improvements in respiratory support and exogenous 
surfactant.  Following an NIH Consensus Conference in 1994, ACS therapy 
has become standard of care in many countries and currently is used as an 
indicator of quality of maternity care in the U.S.  Elevated corticosteroid in 
utero hastens development of glucocorticoid-responsive tissues and results 
in reduced incidence of respiratory distress syndrome, intraventricular 
hemorrhage, necrotizing enterocolitis and death for preterm infants (1).  
Moreover, with the dosing regimen commonly used (12 mg IM q 24 x 2 of 
betamethasone phosphate + betamethasone acetate (Celestone 
Soluspan®)), short-term risks for the mother and infant are minimal.  In 
countries where ACS therapy is available and widely used, a sizeable 
percentage of pregnant women could potentially receive this therapy for 
early preterm labor, late preterm labor and elective cesarean section without
labor.  However, much of the world’s population does not have access to the 
drug and/or appropriate perinatal medical services.  
 The concept of ACS to enhance fetal maturity began with observations
by Liggins in the 1960s (2).  Working with a sheep model to investigate 
mechanisms of parturition, he serendipitously observed that lambs born 
prematurely after dexamethasone treatment had partial lung inflation.  He 
proposed that corticosteroid exposure had accelerated fetal maturity, 
including lung development and surfactant production.  This seminal 
observation led to a clinical trial of ACS in women, and the positive results 
reported in 1972 have been confirmed in numerous subsequent trials (1).  
Liggins and Howie chose a dose of 12 mg Celestone Soluspan, repeated at 
24 hours, with the expectation that rapid hydrolysis of the phosphate form 
would provide early peak levels of betamethasone and that slower hydrolysis
of the acetate form would give sustained exposure (3).  This hypothesis was 
confirmed by measurements of betamethasone in cord blood, with peak 
levels at ~1 h (20 ng/ml) and a prolonged half-life (~12 h) (4).  These plasma
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levels of betamethasone, which provide a physiologic stress level of 
glucocorticoid (4), should provide a near-maximal maturational response in 
the fetus based on studies of surfactant-related components in cultured 
human fetal lung (5).  Indeed, in a subsequent trial, Liggins found no 
improved efficacy for preventing RDS using twice the dose of Celestone (24 
mg; Liggins, personal communication).  However, targeting the lowest 
efficacious dose should be the goal of any therapy.
Can the dosing regimen for ACS be improved with regard to 
risk:benefit and individualizing treatment?  Certainly, the same dose of ACS 
is not optimal for women at extremes of body weight, as demonstrated by 
the pharmacokinetic data of Della Torre (6), and we recommend that dosing 
be given on a per kg basis as used for many other drugs.  Assuming an 
average maternal weight at 26 weeks gestation of 80 kg as representative of
women in published clinical trials of ACS, the recommended dose of 
Celestone would be 0.15 mg/kg given IM.  Complications of pregnancy 
affecting placental function may alter corticosteroid passage from mother to 
fetus; however, this possibility needs further study before considering an 
adjustment to the dose.  Other forms of glucocorticoid might provide better 
pharmacokinetics of fetal exposure; however, hydrocortisone is not 
preferable, because of high peak levels and fast clearance, increasing risk for
off-target effects and un-sustained maturational responses (7).
In this issue of the Journal, Schmidt and colleagues report 
pharmacokinetics and biologic effects of oral ACS therapy for lung 
maturation in sheep (8).  It is astonishing to realize that, as these authors 
point out, “despite being used for nearly 50 years, the corticosteroid, dose, 
treatment interval and route of treatment remain largely unexplored (8).”  
Thus, although the guiding principle of therapeutics is to give the lowest 
effective dose, we have yet to determine such a dose for antenatal 
glucocorticoids.  This principle is particularly important for glucocorticoids, 
which have multiple powerful effects, and even more so when treating the 
preterm fetus, who normally has a low cortisol concentration (9).  Although 
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antenatal steroids clearly have multiple benefits that outweigh theoretical 
risks for infants born preterm, data suggest that prenatal exposure may also 
have long-term effects on infants delivered at term gestation (10-12).  Since 
a large percentage of women given antenatal glucocorticoids do not deliver 
preterm, it is vital to decrease the exposure of fetuses who do not derive the 
benefits of ACS on preterm birth but may experience later effects (10).
The authors first investigated physiologic responses and 
pharmacokinetics of a single 0.33mg/kg dose of oral betamethasone 
phosphate or dexamethasone phosphate (calculated to compensate for an 
estimated bioavailability of 80% of the intramuscular dose).  A single dose of 
oral betamethasone phosphate had comparable lung maturational effects to 
intramuscular Celestone at two days, but had lost efficacy by 5 days, likely 
due to its shorter half-life compared to betamethasone acetate.  However, 
when two doses of 0.16mg/kg were given 24 hours apart, the pulmonary 
effects of oral betamethasone were similar to the effects of IM Celestone 
through the end of the 7-day study period.  In addition, this regimen resulted
in a lower peak concentration than the single oral dose or the IM dose, thus 
decreasing fetal exposure to the drug.  
In a surprising finding, they discovered that the same dose of 
dexamethasone resulted in 4-fold lower serum concentrations in both 
maternal and fetal plasma and had no significant effect on lung maturation.  
However, based on limited human pharmacokinetic data (4, 13-16), the 
difference between dexamethasone and betamethasone bioavailability 
observed in sheep does not occur in humans. In addition, the maternal:fetal 
distribution is different in sheep than in humans, requiring higher dosing in 
the sheep.  These species differences serve as a reminder of the need to be 
vigilant regarding the limitations of animal models for human biology.  The 
numerous obstacles to studying corticosteroid pharmacokinetics and biologic
effects in pregnant women and fetuses will be difficult to surmount, but it is 
encouraging that a comparative pharmacokinetic study is underway in 
women (NCT03668860). The current report provides clear proof of principle 
4
that, in the sheep, oral administration of betamethasone enhances lung 
maturation.  In addition, these results suggest that a lower dose of oral 
betamethasone or dexamethasone phosphate may provide efficacy 
comparable to Celestone while decreasing peak fetal exposure for human 
infants.   
Oral dosing of ACS for lung maturation in human newborn infants 
would be a lower-cost, more easily accessible treatment option, potentially 
leading to broader global adoption. However, the unexpected increase in 
infections and neonatal mortality seen in a previous trial of ACS (IM 
dexamethasone) in low-middle income countries is a reminder that 
numerous known and unknown factors will influence outcomes in different 
countries and health care delivery settings (17). Citing a “clear justification 
for further randomized controlled trials to evaluate the efficacy of ACS in 
facility settings in lower-income countries,” the World Health Organization 
established an international research collaboration to undertake two trials of 
antenatal corticosteroids in pregnancies at risk of preterm delivery, one 
enrolling women before 34 weeks gestation and the second between 340 and
360 weeks gestation (18).  
If proven beneficial through careful clinical trials with comprehensive 
evaluation, a lower dose and oral administration would be an enormous step 
toward making “the most effective underutilized treatment available to 
improve outcomes for fetuses at risk for preterm delivery (8)” more globally 
available and safer.   Ultimately, children and society in general will be best 
served by improved availability and resources for family planning and 
perinatal care combined with optimal preventative therapy for improving the
outcome of infants born prematurely. 
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